Protein tyrosine phosphatase PTPN22 +1858C/T polymorphism is associated with active vitiligo
暂无分享,去创建一个
J. Ocampo-Candiani | R. Ortíz-López | R. Cerda-Flores | C. Sánchez-Domínguez | M. Salinas-Santander | M. García-Meléndez | Hugo Gonzalez-Cárdenas
[1] J. Lambert,et al. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[2] D. Parsad,et al. Stability in Vitiligo: Is there a Perfect Way to Predict it? , 2013, Journal of cutaneous and aesthetic surgery.
[3] Javier Martín,et al. Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis , 2013, Molecular vision.
[4] R. E. Abu Khalil,et al. PTPN22 gene polymorphism in Egyptian females with non-segmental vitiligo , 2013, Comparative Clinical Pathology.
[5] Y. Lee,et al. The CTLA-4 +49A/G, CT60A/G and PTPN22 1858 C/T polymorphisms and susceptibility to vitiligo: a meta-analysis , 2012, Molecular Biology Reports.
[6] H. Rangel-Villalobos,et al. The +1858C/T PTPN22 gene polymorphism confers genetic susceptibility to rheumatoid arthritis in Mexican population from the Western Mexico. , 2012, Immunology letters.
[7] S. Amur,et al. Sex differences and genomics in autoimmune diseases. , 2012, Journal of autoimmunity.
[8] Jeffrey S. Chang,et al. PTPN22 C1858T and the risk of psoriasis: a meta-analysis , 2012, Molecular Biology Reports.
[9] Garth L Burn,et al. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? , 2011, FEBS letters.
[10] R. Sánchez-Porras,et al. Immunopathogenesis of vitiligo. , 2011, Autoimmunity reviews.
[11] K. Siminovitch,et al. The autoimmune disease–associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness , 2011, Nature Genetics.
[12] Dariush Moussai,et al. Th17 Cells and Activated Dendritic Cells Are Increased in Vitiligo Lesions , 2011, PloS one.
[13] Yu. V. Kudryashova,et al. Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population , 2011, Aging.
[14] E. Dellambra,et al. Vitiligo: pathogenetic hypotheses and targets for current therapies. , 2010, Current drug metabolism.
[15] D. Grattapaglia,et al. Allele and haplotype frequency distribution in PTPN22 gene across variable ethnic groups: Implications for genetic association studies for autoimmune diseases , 2010, Autoimmunity.
[16] M. Aris. Origen del melanocito normal y maligno , 2009 .
[17] M. Hermiston,et al. PTPN22 Deficiency Cooperates with the CD45 E613R Allele to Break Tolerance on a Non-Autoimmune Background1 , 2009, The Journal of Immunology.
[18] A. Xu,et al. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo , 2009, International journal of dermatology.
[19] M. Aris,et al. Origin of normal and malignant melanocytes , 2009 .
[20] R. Spritz,et al. The PTPN22‐1858C>T (R620W) functional polymorphism is associated with generalized vitiligo in the Romanian population , 2008, Pigment cell & melanoma research.
[21] V. Sehgal,et al. Vitiligo: compendium of clinico-epidemiological features. , 2007, Indian journal of dermatology, venereology and leprology.
[22] Sheri L. Riccardi,et al. NALP1 in vitiligo-associated multiple autoimmune disease. , 2007, The New England journal of medicine.
[23] N. Bottini,et al. Protein tyrosine phosphatase PTPN22 in human autoimmunity , 2007, Autoimmunity.
[24] D. Gawkrodger,et al. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. , 2007, Autoimmunity reviews.
[25] R. Spritz. The genetics of generalized vitiligo and associated autoimmune diseases. , 2007, Pigment cell research.
[26] L. Orozco,et al. Association analysis of the PTPN22 gene in childhood-onset systemic lupus erythematosus in Mexican population , 2006, Genes and Immunity.
[27] C. Farrar,et al. Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients. , 2006, Rheumatology.
[28] R. Begum,et al. Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes. , 2006, Indian journal of experimental biology.
[29] R. Schwartz,et al. Vitiligo: a sign of systemic disease. , 2006, Indian journal of dermatology, venereology and leprology.
[30] D. Gawkrodger,et al. A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo , 2005, Genes and Immunity.
[31] Xuejun Zhang,et al. The genetic concept of vitiligo. , 2005, Journal of dermatological science.
[32] J. Rodríguez-López,et al. Vitíligo. Tratamiento de 12 casos con tacrolimus tópico , 2005 .
[33] J. Rodríguez-López,et al. [Vitiligo. Treatment of 12 cases with topical tacrolimus]. , 2005, Actas dermo-sifiliograficas.
[34] Nunzio Bottini,et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes , 2004, Nature Genetics.
[35] S. Dogra,et al. Health and Quality of Life Outcomes , 2003 .
[36] E. Shaoul,et al. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. , 1999, Blood.